Clinical Trials Browser

Immunotherapy Gastrict Cancer × tislelizumab × Gastrointestinal × Clear all

NCT05699655 2024-05-01

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2/3 Recruiting

Gastrointestinal

Immunotherapy Gastrict Cancer